Biohealth Innovation
BioHealth Innovation, Inc., (BHI) a non-profit organization which strives to facilitate the development of commercially viable bio health products and companies by connecting market relevant research assets to appropriate funding, management and markets, is seeking a Senior Analyst.
JOB TITLE – SENIOR ANALYST
Reporting to the Lead Entrepreneur in Residence (EIR), the Senior Analyst
BioHealth Innovation (BHI) is an innovation intermediary that facilitates the commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia). We are seeking a Life Sciences Business Strategist to join our team remotely.
The right candidate will be an energetic and continuous learner who is passionate about accelerating the adoption of new technologies to improve lives. The position is geared toward an early-career scientist (generally in their first 5-7 years after receiving their PhD) who wants to engage with the biohealth industry in new ways.
Our Strategists support selected growth-stage businesses beyond commercialization plans and federal grant proposals—they cultivate important relationships with client entrepreneurs and innovators. The Strategists’ work also includes collaborating with expert Entrepreneurs-In-Residence from around the country and other professionals in BHI’s network who have built careers at the intersection of business and science.
GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).
Did you know… The U.S. Department of Health and Human Services is one of the largest sources of early-stage capital for life sciences in the U.S.? There is more than $1.2 billion of seed funding for small businesses that are developing innovative products and services that could potentially save lives.
Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world.
The Seraxis solution is a simple approach to diabetes. Chief Executive Officer Dr. William Rust explained that the therapy replaces damaged or lost insulin-producing pancreatic cells with those grown in the Seraxis labs. In order to accomplish this, Seraxis has developed a proprietary human stem cell line dubbed SR1423 which is special.
TEDCO Talks: A new virtual series featuring thought leaders in economic development from across the State of Maryland.
Join TEDCO's CEO & Executive Director, Troy LeMaile-Stovall, in thought-provoking conversations with regional leaders about the future of Maryland’s innovation ecosystem.
Troy had the opportunity to interview Rich Bendis with BioHealth Innovation. Watch now to learn more about BioHealth Innovation, and the role Rich has played in supporting Maryland's entrepreneurial community.
https://www.youtube.com/watch?v=2dYM3vQAIEU
Every year or so at Crunchbase News, we take a look at which U.S. universities graduate the highest number of funded startup founders. And each time, we find few surprises in the top rankings.
The leading schools for funded founders are reliably Stanford, Harvard and MIT. The top regions are California and the Northeast. And the top business schools are Harvard, Stanford and Wharton.
Image: https://news.crunchbase.com
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso® (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. This is the second FDA-approved indication for Tyvaso, which was first approved in July 2009 for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
The U.S. Department of Health and Human Services launched an innovation challenge competition today encouraging American inventors to aid the nation's COVID-19 response by designing effective, comfortable face masks for personal use that resolve the common complaints people have about wearing masks. The contest taps into the nation's creativity and entrepreneurial spirit to help curb the spread of SARS-CoV-2, the virus that causes COVID-19.
Image: https://www.medicalcountermeasures.gov
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Commercial Banking, notes that investment in life sciences reached record-high levels across almost every category and subsector—despite unprecedented business challenges. Here are a few of the highlights:
Image: https://www.jpmorgan.com
Maryland universities ranked first among the nation's top graduate programs and schools in three out of 15 categories.
Image: State House (from Francis St.), Annapolis, Maryland, February 2014. Photo by Diane F. Evartt.
BERLIN (Reuters) - Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator FDA, it said on Monday.
"This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes," the company said in a statement.
Identifying gaps and bridging them—that’s what Connected DMV’s President and CEO Stu Solomon does best. And now he and his partners are turning their attention to one of the globe’s most important and challenging divides: Preparing for the next pandemic.
Solomon recently discussed his career and Connected DMV’s response to COVID-19 with Rich Bendis on his BioTalk podcast. Bendis is the President and CEO of BioHealth Innovation (BHI).
MainStreet qualifies software, hardware, and venture-backed startups for 200+ unclaimed tax credits accountants don't check for.
We do all the paperwork and you get cash. If we can't help you claim any credits, you pay $0.
GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. The parties will negotiate a final agreement to include additional terms and conditions.
As the supply of Covid-19 vaccines begins to widen toward meeting the immense demand, some observers have proposed that policy makers put college students close to the top of the list.
Christopher R. Marsicano, head of the College Crisis Initiative at Davidson College, argued in a recent op-ed that vaccinating college students would help protect everyone. “The broader principle in administering vaccine shots equitably is to diminish the risk for those who are most at danger to spread the virus,” he wrote. “Vaccinating college students is an effective way to lower that danger, for two major reasons: College students are mobile and spread Covid-19 with them whenever they travel, and they live in congregate living facilities where infection rates are much higher than in other housing setups.”
Image: https://www.chronicle.com/
The region has been at the forefront of the SARS-CoV-2 vaccine race, and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.
Image: https://biobuzz.io
The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.
The top recipients of NIH funding in the BHCR were research universities, with Johns Hopkins University topping the list with $807,432,003 in financing for different research programs. The top 10 recipients of NIH funding in the BioHealth Capital Region secured more than $2.18 billion in financing. Life sciences organizations within the state of Maryland secured $2.3 billion in NIH funding, an increase from the $1.9 billion granted in 2019.
“I’m delighted by GSK’s investment, which shows the strength of UK manufacturing, and will further boost our vaccine rollout. The Vaccines Taskforce has worked hand in glove with business to successfully deliver vaccines to the whole of the UK, and this agreement will continue to support our approach. We remain on track to offer a first jab to all over 50s by 15 April, and all adults by the end of July, and I want to once again encourage everyone to come forward for a vaccine when you’re called,” said Prime Minister Boris Johnson.
TCR² Therapeutics Inc., based in Cambridge, is a clinical-stage company that develops T-cell therapies for patients with cancer. In a statement, TCR² said it signed a long-term, full-building lease for an existing 85,000 sq. ft. facility. The company will build-out the space to be used for quality control laboratories and offices as well as clinical and commercial production of gavo-cel, the company’s lead product targeting solid tumors. According to a federal form, 15 years is the initial term for the lease at 9950 Medical Center Drive.
Montgomery County, Maryland County Executive Marc Elrich has notified the Montgomery County Council of his appointment of BHI's Managing Director for Economic Development, Judy Costello, as Special Projects Manager. Confirmation is expected to take place next month.
“While we are excited for Judy and know she will bring her economic development expertise and passion for supporting innovation and entrepreneurship to the County, we will miss her positive attitude and support of many of our different programs,” said BHI CEO Rich Bendis. “We now are actively recruiting for her position. Anyone interested is welcome to contact me directly.”
Development of Countermeasures for Viral Diseases
The best defense against viral infectious diseases are safe and effective medical countermeasures that function at level of prevention of infection (prophylaxis) and treatment of disease (therapeutic). These include microbicides and vaccines, direct acting antivirals, and immunotherapies. This fireside chat will focus on features and characteristics of effective countermeasures, how they defend against viral infection and disease, and the preclinical development pathways to advance them from bench to bedside.
CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturing Practice (cGMP) build-out. The site will support clinical and commercial production of gavo-cel with a capacity to treat several thousand cancer patients annually. The facility is expected to accelerate the Company’s commercial-scale manufacturing timelines with production anticipated in 2023.
BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract valued at up to $67.4 million for the advanced development of a smallpox biodefense therapeutic.
What did we learn during the pandemic, and what should we watch moving forward?
Those are two of the key questions that many professional conversations center on these days. On Thursday, they were approached by a group of digital health experts who came together for a virtual forum organized by the Economic Alliance of Greater Baltimore and Rockville-based BioHealth Innovation.
Image: Panelists at EAGB and BioHealth Innovation's Digital Health Forum. (Courtesy image)
SPACE FEATURES
You may not know it, but one company has the capacity to manufacture bulk drug substance for more than a billion doses of COVID-19 vaccines annually: Emergent BioSolutions, a global supplier for the Johnson & Johnson vaccine and U.S. supplier for the AstraZeneca vaccine. Emergent Executive Vice President of Manufacturing and Technical Operations Sean Kirk spoke with us recently to explain what goes into the heroic production of all these doses—in other words, what it takes to help defeat COVID-19.
Image: https://www.nam.org/
The University of Maryland hosted a free webinar, Leveraging Artificial Intelligence in Human Health, on Friday, March 19, 2020. This event featured a fireside chat with Dr. Robert Scharpf (Delfi Diagnostics) and Dr. Christie Bergerson (Exponent), moderated by Rich Bendis (BioHealth Innovation/BioTalk podcast).
Together, the group shared insights into how artificial intelligence is impacting biomedical engineering and the wider world of human health, and spoke candidly about future applications for these and other biotech platforms.
Image: https://biocomp.umd.edu
Exciting things are happening at Innovation Park in Manassas. Researchers are working on global solutions, industry jobs are on the rise, and new facilities are being developed – and wait, there’s more!
“Companies are seeing really big wins across the state and the region and the life science industry is only going uphill from here,” said Amy Adams, Executive Director for the Institute for Biohealth Innovation at George Mason University (GMU).
Check out this weeks episode of Talent Talks on YouTube and Spotify! This week we sit with Richard Bendis President and CEO of BioHealth Innovation, Inc. He talks about the importance of knowing your assets and the region around you with our hosts Robb Hoyle CEO GTS Scientific and Gregory Hoyle. Click below to watch and make sure to like and subscribe: https://hubs.li/H0JRgfF0
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. March is WOMEN’S HISTORY MONTH and BioBuzz will celebrate by featuring Women in the BioHealth industry all month, especially in “5 Questions With…”. This week we continue the series with Natalie McKinney, Industry Programs Director, Biologics, US Pharmacopeia.
New buildings are now rising out of the ground on the first major phase of construction at the 235-acre, $5.5-billion, multi-decade Port Covington development. Construction on five new buildings totaling 1.1 million sq. ft. is underway with a tower crane currently on the site. The Port Covington Development Team held a groundbreaking today to celebrate the start of vertical construction.
Image: https://www.southbmore.com
ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share. CASI has granted the underwriters an option to purchase up to an additional 2,378,048 shares of common stock, which terminates on the earlier of 30 days and the day before CASI files to the U.S. Securities and Exchange Commission ("SEC") its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The offering is expected to close on or about March 26, 2021, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their option to purchase additional shares, are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.
ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 shares of common stock, equivalent with 15,666,670 Korea Depository Receipts (KDRs) priced at KRW 37,500 per share, equivalent with KRW 7,500 per KDRs. The aggregate gross proceeds to NeoImmuneTech, before deducting underwriting discounts and commissions and other offering expenses, were KRW 117.5 billion ($103.4 million). NeoImmuneTech’s common stock began trading on the Korea Exchange on March 16, 2021, under the KOSDAQ code number “950220.”
Our AstraZeneca Gaithersburg Campus will be illuminated this week to pay tribute to José Baselga, our beloved Oncology R&D leader and Site Head who passed away last weekend. Our entire community is devasted by this unexpected news following a period of temporary medical leave that he began in January 2021. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and especially here at AstraZeneca Gaithersburg. He set our Oncology R&D function on a remarkable trajectory, and his visionary leadership, deep scientific expertise and strategic insight have delivered so many achievements that will benefit patient lives in the years to come. The blue and garnet lights were chosen to celebrate his favorite hometown soccer club, FC Barcelona. He will be deeply missed across our campus, and we will continue to be inspired by his work and vison.
For any inquiries please reach out to Joe Sanchez at joseph.sanchez @astrazeneca.com.